Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".
作者信息
Nishida Naoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):635-639. doi: 10.3350/cmh.2025.0071. Epub 2025 Jan 24.
Abstract
摘要
相似文献
1
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".肉瘤样肝细胞癌的遗传学见解：ARID2在发病机制和免疫特征中的关键作用：关于“肉瘤样肝细胞癌的综合分子特征”的社论
Clin Mol Hepatol. 2025 Apr;31(2):635-639. doi: 10.3350/cmh.2025.0071. Epub 2025 Jan 24.
2
Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.肉瘤样肝细胞癌的综合分子特征
Clin Mol Hepatol. 2025 Apr;31(2):426-444. doi: 10.3350/cmh.2024.0686. Epub 2024 Dec 10.
3
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".致关于“肉瘤样肝细胞癌的综合分子特征”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e192-e193. doi: 10.3350/cmh.2025.0183. Epub 2025 Feb 26.
4
Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.肝肉瘤样癌是一种侵袭性肝肿瘤，与常规癌性对应物具有共同的分子特征。
Mod Pathol. 2023 Jan;36(1):100042. doi: 10.1016/j.modpat.2022.100042.
5
Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.纳武利尤单抗和伊匹单抗联合治疗转移性肉瘤样集合管癌的完全缓解：高程序性死亡配体 1 表达病例报告。
J Med Case Rep. 2022 May 18;16(1):193. doi: 10.1186/s13256-022-03426-3.
6
HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.乙肝病毒X蛋白介导的无调性同源框蛋白1下调抑制AT丰富区结合蛋白2表达并促进肝细胞癌发生。
Cancer Sci. 2017 Jul;108(7):1328-1337. doi: 10.1111/cas.13277. Epub 2017 Jun 14.
7
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.肾细胞癌中的肉瘤样去分化：从新的分子见解到新的临床机遇
Cancers (Basel). 2019 Dec 31;12(1):99. doi: 10.3390/cancers12010099.
8
Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.肉瘤样肝细胞癌：从临床特征到癌症基因组。
Cancer Med. 2021 Sep;10(18):6227-6238. doi: 10.1002/cam4.4162. Epub 2021 Jul 31.
9
Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.肉瘤样肝细胞癌的免疫浸润特征。
Aging (Albany NY). 2021 Jun 3;13(11):15126-15138. doi: 10.18632/aging.203076.
10
Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors.免疫检查点抑制剂时代肉瘤样肾细胞癌的管理与预后的演变范式
World J Oncol. 2020 Oct;11(5):183-187. doi: 10.14740/wjon1325. Epub 2020 Oct 15.
引用本文的文献
1
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".致关于“肉瘤样肝细胞癌的综合分子特征”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e192-e193. doi: 10.3350/cmh.2025.0183. Epub 2025 Feb 26.
本文引用的文献
1
Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.肉瘤样肝细胞癌的综合分子特征
Clin Mol Hepatol. 2025 Apr;31(2):426-444. doi: 10.3350/cmh.2024.0686. Epub 2024 Dec 10.
2
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
3
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.ARID1A 抑制 R 环介导的 STING 型 I 干扰素通路激活抗肿瘤免疫。
Cell. 2024 Jun 20;187(13):3390-3408.e19. doi: 10.1016/j.cell.2024.04.025. Epub 2024 May 15.
4
Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.哺乳动物 SWI/SNF 复合物亚基基因的突变对免疫肿瘤微环境的影响。
Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):88-101. doi: 10.21873/cgp.20432.
5
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.免疫检查点抑制剂在肝细胞癌中的应用：临床实践中的新挑战。
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):760-770. doi: 10.1016/S2468-1253(23)00147-4. Epub 2023 Jun 14.
6
Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.肝肉瘤样癌是一种侵袭性肝肿瘤，与常规癌性对应物具有共同的分子特征。
Mod Pathol. 2023 Jan;36(1):100042. doi: 10.1016/j.modpat.2022.100042.
7
Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.肉瘤样肝细胞癌患者的基因检测与预后
Front Oncol. 2023 Jan 17;12:1086908. doi: 10.3389/fonc.2022.1086908. eCollection 2022.
8
A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy.采用联合免疫疗法治疗的破裂性肉瘤样肝细胞癌。
Clin J Gastroenterol. 2023 Apr;16(2):244-249. doi: 10.1007/s12328-023-01758-1. Epub 2023 Jan 10.
9
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.阿替利珠单抗联合贝伐珠单抗治疗肉瘤样肝细胞癌（SHCC）患者取得疗效，该患者为 IMbrave150 试验排除的罕见亚型。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221129470. doi: 10.1177/23247096221129470.
10
Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma.肉瘤样肝细胞癌患者的长期结局和预后
Ann Transl Med. 2022 Apr;10(7):394. doi: 10.21037/atm-21-4322.
Zotero 插件